Repeat Surgery for Recurrent Glioblastoma

This trial explores whether repeat surgery for recurrent glioblastoma (GBM), an aggressive brain tumor, can improve patients' quality and length of survival. It aims to provide neurosurgeons with evidence on managing GBM without adding extra risks or tests beyond normal care. The trial includes two groups: one receiving repeat surgery and the other following standard non-surgical care. Suitable participants have had previous surgery for GBM, and their surgeon believes another surgery could enhance their survival quality. As an unphased trial, it allows patients to contribute to research that could improve future treatment strategies.

The trial protocol does not specify whether you need to stop taking your current medications.

Research has shown that undergoing another surgery for recurrent glioblastoma might extend patient survival, but it carries certain risks. One study found that patients who had a second surgery lived an average of 23.9 months, compared to 9.2 months for those who had only one surgery. However, the likelihood of post-surgery complications is higher. Specifically, another study found that about 4.9% of patients experienced complications lasting three months or more. Despite this, many patients do not face long-term issues. Considering these potential risks and benefits is crucial when evaluating the option of another surgery.¹²³⁴⁵

Researchers are excited about repeat surgical management for recurrent glioblastoma because it offers a potential new approach to a very challenging condition. Unlike standard treatments that might include chemotherapy, radiation, or single surgeries, this method explores whether undergoing another surgery can better manage the tumor's regrowth. By comparing outcomes of repeat surgery against non-surgical management, researchers aim to understand if this approach could extend survival or improve quality of life for patients dealing with this aggressive brain cancer.

Research has shown that another surgery for returning glioblastoma (GBM) can extend life expectancy. In this trial, participants in the "Repeat Surgical Resection" arm will undergo an additional surgery. One study found that patients who had a second surgery lived an average of 23.9 months, compared to 9.2 months for those who only had one surgery. Another study demonstrated that a second surgery improved survival rates, regardless of the patient's age or health condition. Additionally, patients who had more of the tumor removed during the second surgery lived longer than those with less removed. These findings suggest that another surgery might help people with returning GBM live longer and spend more time outside of hospitals.¹⁵⁶⁷⁸